Manufacturer profile
ATLANTIC BIOLOGICALS CORP.
Pharmaceutical company2 products tracked
2
products tracked
43,589
total reports
4
recalls on record
82.5%
serious overall
Products
showing 2 of 2
| Product | Approved | Reports ↓ | Top signal | Recalls |
|---|---|---|---|---|
| — | 39,800 | Gambling disorder | 0 | |
| 1971 | 3,789 | Adrenal insufficiency | 4 |
Recall history · 4 on record
| Date | Class | Reason | Firm |
|---|---|---|---|
| Apr 26, 2023 | II | CGMP Deviations: Firm went out of business and could no longer continue stability studies. | Akorn, Inc. |
| Nov 6, 2018 | III | Failed Stability Specifications: Out-of-Specification results obtained for particle size distribution during stability testing. | Breckenridge Pharmaceutical, Inc. |
| Aug 14, 2018 | II | Supterpotent Drug | Mckesson Corporation |
| Jan 29, 2018 | III | Subpotent Drug: Out of specification for assay (stability testing) | Mckesson Packaging Services |
Class I = reasonable probability of serious harm · Class II = temporary or reversible · Class III = unlikely to cause harm.
Registration status
Some products from ATLANTIC BIOLOGICALS CORP. are not FDA-registered for human use. For unregistered substances (peptides, SARMs without human registration), no legitimate human-use supplier exists. The absence of a sourcing route is the safety information.